Bruce Koch
Executive Director, Medical Affairs at Portola Pharmaceuticals Inc - South San Francisco, CA, US
Bruce Koch's Colleagues at Portola Pharmaceuticals Inc
Kimberlyn Seideman
Senior Manager, Commercial and Clinical Packaging and Labeling
Bruce Koch's Contact Details
650-246-7000
San Francisco Bay Area
Portola Pharmaceuticals Inc
Bruce Koch's Company Details
We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. We are continuing to explore new discoveries that impact how serious blood-related disorders are treated and expanding the potential impact of our existing portfolio of medicines.